1. Adams, C.M., Goldstein, J.L., and Brown, M.S., Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles, Proc. Natl. Acad. Sci. U. S. A., 2003, vol. 100, pp. 10647–10652.
2. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P, Cappelleri, J.C., Infante, M.C., and Weiden, P.J., Antipsychotic-induced weight gain: a comprehensive research synthesis, Am. J. Psychiatry, 1999, vol. 156, pp. 1686–1696.
3. Bartoli, F., Crocamo, C., Clerici, M., and Carrà, G., Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis, Eur. Neuropsychopharmacol., 2015, vol. 25, pp. 1767–1774.
4. Bezborodkina, N.N., Okovity, S.V., and Kudriavtsev, B.N., Uglevodnyi metabolizm pri khronicheskikh porazheniyakh pecheni (Metabolism of Carbohydrates in Chronic Liver Diseases), St. Petersburg: Sintez Book, 2008.
5. Burris, K.D., Molski, T.F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F.D, and Molinoff, P.B., Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors, J. Pharmacol. Exp. Therap., 2002, vol. 302, pp. 381–389.